Anti-SARS-CoV-2 IgM Antibody Levels Measured by an In-House ELISA in a Convalescent Latin Population Persist over Time and Exhibit Neutralizing Capacity to Several Variants of Concern

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2024 Oct 16

PMID 39410613

Authors

Ana M Espino

Albersy Armina-Rodriguez

Paola Cardona

Carlimar Ocasio-Malave

Laura Alvarez

Carlos A Sariol

Affiliations

Soon will be listed here.

Abstract

Background: The coronavirus, SARS-CoV-2, is the causative agent for COVID-19, first registered in Wuhan, China and responsible for more than 6 million deaths worldwide. Currently, RT-PCR is the gold-standard method for diagnosing COVID-19. However, serological tests are needed for screening acute disease diagnosis and screening large populations during the COVID-19 outbreak.

Objectives: Herein, we described the development and validation of an in-house enzyme-linked immunosorbent assay (ELISA) for detecting the levels of anti-spike-1-RBD IgM antibody (CovIgM-ELISA) in well-defined serum/plasma panel for screening and identifying subjects infected with SARS-CoV-2 in a Latin population.

Method: In-house CovIgM-ELISA has the format of an indirect ELISA. It was optimized by checkerboard titration using recombinant SARS-CoV-2 spike-S1-RBD protein as an antigen.

Results: We found that, compared to the RT-PCR as the standard method, the in-house CovIgM-ELISA displayed sensitivities of 96.15% and 93.22% for samples collected up to 30 or 60 days after infection, respectively, as well as 95.59% specificity with 97.3% accuracy. The agreement kappa value () of our CovIgM-ELISA was substantial when compared to RT-PCR (κ = 0.873) and the anti-SARS-CoV-2 IgM ELISA (InBios Int) (κ = 0.684). The IgM levels detected in the population positively correlated with the neutralizing activity against the wild-type, Alpha and Delta variants of concern, but failed to neutralize Omicron.

Conclusions: These data indicate that our in-house CovIgM-ELISA is a compatible performing assay for the detection of SARS-CoV-2 infection.

References

Espino A, Armina-Rodriguez A, Alvarez L, Ocasio-Malave C, Ramos-Nieves R, Rodriguez Martino E . The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer-BioNTech Vaccine. Viruses. 2024; 16(2). PMC: 10893502. DOI: 10.3390/v16020187. View

. Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. Euro Surveill. 2020; 25(5). PMC: 7014669. DOI: 10.2807/1560-7917.ES.2020.25.5.200131e. View

Klingler J, Weiss S, Itri V, Liu X, Oguntuyo K, Stevens C . Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. medRxiv. 2020; . PMC: 7654883. DOI: 10.1101/2020.08.18.20177303. View

Addetia A, Crawford K, Dingens A, Zhu H, Roychoudhury P, Huang M . Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol. 2020; 58(11). PMC: 7587101. DOI: 10.1128/JCM.02107-20. View

Valdes-Fernandez B, Duconge J, Espino A, Ruano G . Personalized health and the coronavirus vaccines-Do individual genetics matter?. Bioessays. 2021; 43(9):e2100087. PMC: 8390434. DOI: 10.1002/bies.202100087. View

Wolfel R, Corman V, Guggemos W, Seilmaier M, Zange S, Muller M . Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581(7809):465-469. DOI: 10.1038/s41586-020-2196-x. View

Ha B, Jadhao S, Hussaini L, Gibson T, Stephens K, Salazar L . Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. Microbiol Spectr. 2021; 9(2):e0045821. PMC: 8557898. DOI: 10.1128/Spectrum.00458-21. View

Oka S, Higuchi T, Furukawa H, Shimada K, Hashimoto A, Matsui T . False-positive detection of IgM anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with rheumatoid arthritis: Possible effects of IgM or IgG rheumatoid factors on immunochromatographic assay results. SAGE Open Med. 2022; 10:20503121221088090. PMC: 8949754. DOI: 10.1177/20503121221088090. View

Kaduskar O, Gurav Y, Deshpande K, Desphande G, Yadav P, Rakhe A . Understanding the dynamics of IgM & IgG antibodies in COVID-19-positive patients. Indian J Med Res. 2022; 155(5&6):565-569. PMC: 9807202. DOI: 10.4103/ijmr.IJMR_675_21. View

10.

Sariol C, Pantoja P, Serrano-Collazo C, Rosa-Arocho T, Armina-Rodriguez A, Cruz L . Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination. Viruses. 2021; 13(10). PMC: 8538099. DOI: 10.3390/v13101972. View

11.

Joyner M, Senefeld J, Klassen S, Mills J, Johnson P, Theel E . Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. medRxiv. 2020; . PMC: 7430623. DOI: 10.1101/2020.08.12.20169359. View

12.

Wieckowska B, Kubiak K, Jozwiak P, Moryson W, Stawinska-Witoszynska B . Cohen's Kappa Coefficient as a Measure to Assess Classification Improvement following the Addition of a New Marker to a Regression Model. Int J Environ Res Public Health. 2022; 19(16). PMC: 9407914. DOI: 10.3390/ijerph191610213. View

13.

Al-Tamimi M, Tarifi A, Qaqish A, Abbas M, Albalawi H, Abu-Raideh J . Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals. PLoS One. 2023; 18(2):e0281689. PMC: 9928079. DOI: 10.1371/journal.pone.0281689. View

14.

Wang P . Combination of serological total antibody and RT-PCR test for detection of SARS-COV-2 infections. J Virol Methods. 2020; 283:113919. PMC: 7295513. DOI: 10.1016/j.jviromet.2020.113919. View

15.

Amellal H, Assaid N, Charoute H, Akarid K, Maaroufi A, Ezzikouri S . Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study. PLoS One. 2023; 18(7):e0288557. PMC: 10337929. DOI: 10.1371/journal.pone.0288557. View

16.

Chakraborty C, Bhattacharya M, Sharma A, Mallik B . Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. Int J Biol Macromol. 2022; 219:980-997. PMC: 9359758. DOI: 10.1016/j.ijbiomac.2022.07.254. View

17.

Higgins V, Fabros A, Wang X, Bhandari M, Daghfal D, Kulasingam V . Anti-SARS-CoV-2 IgM improves clinical sensitivity early in disease course. Clin Biochem. 2021; 90:1-7. PMC: 7816645. DOI: 10.1016/j.clinbiochem.2021.01.003. View

18.

El-Daly M . Advances and Challenges in SARS-CoV-2 Detection: A Review of Molecular and Serological Technologies. Diagnostics (Basel). 2024; 14(5). PMC: 10931201. DOI: 10.3390/diagnostics14050519. View

19.

Miranda E, Han X, Park S, Suri S, Suryavanshi M . Treatment Patterns Among Patients with Rheumatoid Arthritis in Puerto Rico. Rheumatol Ther. 2022; 9(2):609-619. PMC: 8964873. DOI: 10.1007/s40744-021-00408-7. View

20.

Suhandynata R, Hoffman M, Kelner M, McLawhon R, Reed S, Fitzgerald R . Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19. J Appl Lab Med. 2020; 5(5):908-920. PMC: 7313967. DOI: 10.1093/jalm/jfaa079. View